Literature DB >> 12875097

The long-term outcomes of drug use by methadone maintenance patients.

Gregory Bovasso1, John Cacciola.   

Abstract

The aim of the study is to predict long-term outcomes of methadone maintenance (MM), other than continued heroin use, on the basis of drug use occurring early in MM treatment. In previous research, the weak association of initial drug use during MM with measures of rehabilitation status may be due to the use of measures that do not differentiate trends in different types of drug use. In the present study, 222 patients who completed 6 months of MM were assessed at program intake, evaluated for opiates and cocaine in the first 6 months of treatment, and given a follow-up assessment 2 years after treatment entry. The intake status of the patients was assessed using the Addiction Severity Index. Opiate and cocaine use during the first 6 months of MM was assessed by urine toxicology. Outcomes were assessed using a structured interview and official criminal records at follow-up. Cluster analysis of urine toxicologies during treatment identified 3 trajectory classes of MM patients: (A) variably high levels of opiate use, but consistently low cocaine use; (B) low and diminishing opiate and cocaine use; and (C) consistently high cocaine use, with diminishing opiate use. In an 18-month period, after these trends were observed, Cluster C had significantly more criminal charges than Cluster B had (3 times as many), but not significantly more than those of Cluster A. Clusters A and B did not differ significantly in criminal charges. Regardless of cluster membership, subjects with increasing levels of cocaine use in the first 6 months of MM had more hospitalizations for drug and alcohol problems during the follow-up period than subjects without increasing levels of cocaine use had. The results provide evidence of negative sequelae of cocaine use during MM that underscore the importance of clinical efforts to reduce levels of cocaine and other nonopiate drug use by MM patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12875097     DOI: 10.1007/bf02287318

Source DB:  PubMed          Journal:  J Behav Health Serv Res        ISSN: 1094-3412            Impact factor:   1.505


  20 in total

1.  Natural classes of treatment response.

Authors:  A R Morral; M Y Iguchi; M A Belding; R J Lamb
Journal:  J Consult Clin Psychol       Date:  1997-08

2.  The effectiveness of methadone maintenance treatment: an overview.

Authors:  J Ward; R P Mattick; W Hall
Journal:  Drug Alcohol Rev       Date:  1994

3.  One-year mortality rates following methadone treatment discharge.

Authors:  D A Zanis; G E Woody
Journal:  Drug Alcohol Depend       Date:  1998-11-01       Impact factor: 4.492

4.  Long-term outcome of patients treated with methadone maintenance.

Authors:  V P Dole; H Joseph
Journal:  Ann N Y Acad Sci       Date:  1978       Impact factor: 5.691

5.  Assessment of object relations and reality testing in methadone patients.

Authors:  M J Rutherford; J S Cacciola; A I Alterman; J R McKay
Journal:  Am J Psychiatry       Date:  1996-09       Impact factor: 18.112

Review 6.  Methadone maintenance to abstinence. How many make it?

Authors:  J B Milby
Journal:  J Nerv Ment Dis       Date:  1988-07       Impact factor: 2.254

7.  Enhanced treatment outcomes for cocaine-using methadone patients.

Authors:  A Rosenblum; S Magura; M Palij; J Foote; L Handelsman; B Stimmel
Journal:  Drug Alcohol Depend       Date:  1999-05-03       Impact factor: 4.492

8.  The early course of change in methadone maintenance.

Authors:  J S Cacciola; A I Alterman; M J Rutherford; J R McKay; A T McLellan
Journal:  Addiction       Date:  1998-01       Impact factor: 6.526

9.  Gender differences in diagnosing antisocial personality disorder in methadone patients.

Authors:  M J Rutherford; A I Alterman; J S Cacciola; E C Snider
Journal:  Am J Psychiatry       Date:  1995-09       Impact factor: 18.112

10.  Outcome after methadone treatment: influence of prior treatment factors and current treatment status.

Authors:  E C Strain; M L Stitzer; I A Liebson; G E Bigelow
Journal:  Drug Alcohol Depend       Date:  1994-06       Impact factor: 4.492

View more
  18 in total

1.  Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users.

Authors:  Chinazo O Cunningham; Angela Giovanniello; Hillary V Kunins; Robert J Roose; Aaron D Fox; Nancy L Sohler
Journal:  Am J Addict       Date:  2013 Jul-Aug

2.  Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment.

Authors:  Bohdan Nosyk; Daphne P Guh; Nicholas J Bansback; Eugenia Oviedo-Joekes; Suzanne Brissette; David C Marsh; Evan Meikleham; Martin T Schechter; Aslam H Anis
Journal:  CMAJ       Date:  2012-03-12       Impact factor: 8.262

3.  Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients.

Authors:  Alison Oliveto; James Poling; Michael J Mancino; Zachary Feldman; Joseph F Cubells; Rhonda Pruzinsky; Kishorchandra Gonsai; Christopher Cargile; Mehmet Sofuoglu; Mohit P Chopra; Gerardo Gonzalez-Haddad; Kathleen M Carroll; Thomas R Kosten
Journal:  Drug Alcohol Depend       Date:  2010-09-15       Impact factor: 4.492

4.  Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase.

Authors:  Thomas R Kosten; Guiying Wu; Wen Huang; Mark J Harding; Sara C Hamon; Jaakko Lappalainen; David A Nielsen
Journal:  Biol Psychiatry       Date:  2012-08-18       Impact factor: 13.382

5.  Patterns of use of other drugs among those with alcohol dependence: Associations with drinking behavior and psychopathology.

Authors:  Howard B Moss; Risë B Goldstein; Chiung M Chen; Hsiao-Ye Yi
Journal:  Addict Behav       Date:  2015-06-25       Impact factor: 3.913

6.  Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial.

Authors:  Yih-Ing Hser; Elizabeth Evans; David Huang; Robert Weiss; Andrew Saxon; Kathleen M Carroll; George Woody; David Liu; Paul Wakim; Abigail G Matthews; Mary Hatch-Maillette; Eve Jelstrom; Katharina Wiest; Paul McLaughlin; Walter Ling
Journal:  Addiction       Date:  2016-01-13       Impact factor: 6.526

7.  Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users.

Authors:  Linwei Wang; Jeong Eun Min; Emanuel Krebs; Elizabeth Evans; David Huang; Lei Liu; Yih-Ing Hser; Bohdan Nosyk
Journal:  Int J Drug Policy       Date:  2017-09-06

8.  Dynamics in the costs of criminality among opioid dependent individuals.

Authors:  Emanuel Krebs; Thomas Kerr; Julio Montaner; Evan Wood; Bohdan Nosyk
Journal:  Drug Alcohol Depend       Date:  2014-09-22       Impact factor: 4.492

9.  ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse.

Authors:  Catherine J Spellicy; Thomas R Kosten; Sara C Hamon; Mark J Harding; David A Nielsen
Journal:  Pharmacogenet Genomics       Date:  2013-07       Impact factor: 2.089

10.  Pharmacogenetic randomized trial for cocaine abuse: disulfiram and α1A-adrenoceptor gene variation.

Authors:  D Shorter; D A Nielsen; W Huang; M J Harding; S C Hamon; T R Kosten
Journal:  Eur Neuropsychopharmacol       Date:  2013-07-10       Impact factor: 4.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.